Journal Articles Kidney International Year : 2019

The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward

Abstract

The Spin-D (Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease) and MiREnDa (Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease) trials taken together provide the reassuring demonstration that up to 25 mg/d spironolactone is reasonably safe, provided maintenance hemodialysis patients are properly monitored and investigators use a per-protocol therapeutic algorithm to manage hyperkalemia. These results should encourage and reassure the investigators of the 2 currently ongoing, large, international, major-outcome clinical trials, both of which are using spironolactone up to 25 mg/d: ACHIEVE (Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease trial; NCT03020303) and ALCHEMIST (ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial; NCT01848639).Copyright © 2019 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.
Fichier principal
Vignette du fichier
S0085253819300067.pdf (4) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-02510924 , version 1 (22-10-2021)

Licence

Identifiers

Cite

Patrick Rossignol, Luc Frimat, Faiez Zannad. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney International, 2019, 95 (4), pp.747-749. ⟨10.1016/j.kint.2018.12.006⟩. ⟨hal-02510924⟩
51 View
103 Download

Altmetric

Share

More